License Agreements & Ducentis Acquisition - AstraZeneca (Details) - USD ($) $ in Thousands |
1 Months Ended | 3 Months Ended | 6 Months Ended | ||||
|---|---|---|---|---|---|---|---|
May 30, 2025 |
Oct. 31, 2024 |
Jun. 30, 2026 |
Jun. 30, 2025 |
Sep. 30, 2022 |
Jun. 30, 2026 |
Jun. 30, 2025 |
|
| Research and Development Arrangement, Contract to Perform for Others [Line Items] | |||||||
| Amortization of intangible assets | $ 1,125 | $ 3,542 | |||||
| AstraZeneca | |||||||
| Research and Development Arrangement, Contract to Perform for Others [Line Items] | |||||||
| Product milestone payment for first product approval | $ 7,500 | ||||||
| Sales milestone payment | $ 10,000 | $ 5,000 | |||||
| Annual net sales | $ 250,000 | $ 100,000 | |||||
| Intangible asset, useful life | 10 years | ||||||
| Amortization of intangible assets | $ 600 | $ 600 | 1,100 | 3,500 | |||
| Maximum milestone payments for licensed products | $ 5,000 | ||||||
| Number of years after first commercial sale to receive royalties | 10 years | ||||||
| Royalty expense | $ 3,900 | $ 2,500 | $ 7,100 | $ 4,400 | |||
| X | ||||||||||
- Definition License Agreement, Number Of Years After First Commercial Sale To Receive Royalties No definition available.
|
| X | ||||||||||
- Definition Research and Development Arrangement, Contract to Perform for Others, Annual Worldwide Net Sales Threshold No definition available.
|
| X | ||||||||||
- Definition Research and Development Arrangement, Contract to Perform for Others, Product Milestone Payment For First Product Approval No definition available.
|
| X | ||||||||||
- Definition Research and Development Arrangement, Contract to Perform for Others, Product Milestone Payments No definition available.
|
| X | ||||||||||
- Definition Research and Development Arrangement, Contract to Perform for Others, Sales Milestone Payments No definition available.
|
| X | ||||||||||
- Definition Amount of amortization expense for finite-lived intangible asset. Excludes goodwill and capitalized cost for software to be sold, leased, or marketed. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Useful life of finite-lived intangible asset, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Excludes goodwill and capitalized cost for software to be sold, leased, or marketed. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Details
|